Discovery in human acute myeloid leukemia could provide novel pathway to new treatments
Researchers at Mount Sinai have discovered that human acute myeloid leukemia (AML) stem cells are dependent on a transcription factor known as RUNX1, potentially providing a new therapeutic target to achieve lasting remissions or even cures for a disease in which medical advances have been limited.
In a study published in June in Cell Reports, the team described how they used induced pluripotent stem cells from a patient with AML to recreate leukemia stem cell biology in the lab, revealing that AML leukemia stem cells lose their leukemic properties once the transcription factor is knocked down or deleted. The researchers further showed that AML cells from other patients were RUNX1-dependent.
“Our development of a new leukemia stem cell model for AML allowed us to study these cells in greater detail than ever before, leading to the unexpected finding of specific dependency of leukemia stem cells on the transcription factor RUNX1,” says Eirini Papapetrou, MD, PhD, Associate Professor, Oncological Sciences, at Icahn School of Medicine at Mount Sinai, and senior author of the study. “Digging further, we found earlier studies suggesting that RUNX1 expression is a marker of poor prognosis for patients with acute myeloid leukemia. Our work may now provide an explanation, namely that RUNX1 is required to sustain leukemia stem cells and thus propagate the leukemia.”
Acute myeloid leukemia is a cancer of the blood and bone marrow, the spongy tissue inside bones where blood cells are made. AML, which primarily affects white blood cells, is one of the most common leukemias in adults, with more than 20,000 newly diagnosed cases each year in the United States. While several new drugs have been introduced in recent years targeting the disease, they have fallen short of significantly changing patient outcomes or survival.
Dr. Papapetrou was one of the first investigators to derive patient-specific induced pluripotent stem cells and use them in disease modeling, with the goal of better understanding the mechanisms of acute myeloid leukemia and identifying promising new therapeutic targets. Induced pluripotent stem cells, which won their developer the Nobel Prize in 2012, are generated from adult cells and can be differentiated into almost any type of cell type in the body, making them different from and in some ways preferable to embryonic stem cells. Through the use of induced pluripotent stem cells, Dr. Papapetrou and her research team were able to recapitulate a leukemia stem cell state that was difficult to capture and study with traditional models. “Our model made it much easier to isolate and culture leukemia stem cells over a long period, which meant we could obtain them in large numbers for ongoing research,” she explains.
That work uncovered other intriguing genes that appear to play a role in the mediation of RUNX1 effects in leukemia stem cells. Most prominent is TSPAN 18, which scientists believe could prove to be an even more attractive therapeutic target than RUNX1 since, as a cell surface protein, it can be targeted with antibody or chimeric antigen receptor (CAR) T-cell approaches. TSPAN 18 and other candidate genes that lie downstream of RUNX1 could be future subjects of investigation by Dr. Papapetrou’s lab, which is committed to the study of blood disorders, particularly myeloid malignancies.
Indeed, the lab’s advances with human leukemia stem cells have broader implications for the entire field around therapeutic targeting of leukemia stem cells. “We’re demonstrating that you can’t appreciably affect leukemia without addressing leukemia stem cells,” Dr. Papapetrou emphasizes, adding that her work has provided datasets and characterized gene signatures of AML leukemia stem cells that will be critical to future studies. “It’s impossible to say at this early stage when or if our work will lead to significant improvements or possibly a cure for AML,” she says, “but the results we’ve seen so far are very promising and underscore the tremendous potential in this field.”
Researchers from Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, and University of Miami Miller School of Medicine contributed to this research.
About the Mount Sinai Health System
The Mount Sinai Health System is New York City’s largest integrated delivery system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai’s vision is to produce the safest care, the highest quality, the highest satisfaction, the best access and the best value of any health system in the nation. The Health System includes approximately 7,480 primary and specialty care physicians; 11 joint-venture ambulatory surgery centers; more than 410 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report’s “Best Medical Schools”, aligned with a U.S. News & World Report’s “Honor Roll” Hospital, No. 12 in the nation for National Institutes of Health funding, and among the top 10 most innovative research institutions as ranked by the journal Nature in its Nature Innovation Index. This reflects a special level of excellence in education, clinical practice, and research. The Mount Sinai Hospital is ranked No. 18 on U.S. News & World